Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 380 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Cognitive Impairment, Carotid Artery Plaque, Inflammation
Interventions
Imaging with flutemetamol F 18 PET/CT
Drug
Lead sponsor
Scott Mcnally
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
2
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Accepts healthy volunteers

Spices, Inflammation and Vascular Response in Humans

NCT03926442
Conditions
Healthy
Interventions
Italian Herb meal, Cinnamon Meal, Pumpkin Spice meal, Placebo meal
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Not applicable Interventional Accepts healthy volunteers

DNA Methylation and Vascular Function

NCT03527420
Conditions
Obesity, Vascular Dysfunction
Interventions
Exercise training
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis - Extension Study

NCT01866592
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Resveratrol and Cardiovascular Health in the Elderly

NCT01842399
Conditions
Vascular Resistance, Hypertension
Interventions
Resveratrol, Placebo
Dietary Supplement · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ischemia and Non-obstructive Coronary Arteries
Interventions
Invasive coronary angiography, Coronary Artery Endothelial Cell Sampling, Fitbit, Invasive coronary function testing
Procedure · Device · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Conditions
Total Knee Arthroplasty
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glipizide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Aggressive B-Cell Non-Hodgkin Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, HGBL With MYC and BCL2 and/or BCL6 Rearrangements, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, Non-hodgkin Lymphoma,B Cell, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Epstein-Barr Virus Positive DLBCL, Nos, Follicular Lymphoma Grade 3B, DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Lymphoma Grade 3, Marginal Zone Splenic Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinaemia
Interventions
SynKIR-310
Biological
Lead sponsor
Verismo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Fairway, Kansas + 2 more
Conditions
COPD, Congestive Heart Failure, Trauma, Sepsis, Stroke
Interventions
NexfinHD Monitor
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Coronary Artery Disease, Atherosclerosis, Cardiovascular Inflammation
Interventions
CaRi-Heart® Analysis
Device
Lead sponsor
Corazon Medical PC
Other
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Bay City, Michigan • Berkley, Michigan • Caro, Michigan + 15 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

NCT06489249
Conditions
Electronic Cigarette Use, Endothelial Dysfunction, Inflammation
Interventions
Placebo, Salsalate 750 MG Oral Tablet [DISALCID]
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Iowa City, Iowa
Conditions
Osteoarthritis
Interventions
Exercise Training
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
40 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Conditions
Acute Respiratory Distress Syndrome, Sepsis, Cardiovascular Shock
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
9 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Completed No phase listed Observational

Platelet Reactivity After CABG

NCT01793597
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Coronary Disease, Heart Valve Diseases
Interventions
CTI-01 (ethyl pyruvate)
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Francisco, California + 14 more
Withdrawn No phase listed Observational Accepts healthy volunteers

Immunomodulatory Effects of PCSK9 Inhibition

NCT05720156
Conditions
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation, Vascular Diseases, Vascular Disease, Peripheral, Vascular Calcification, High Cholesterol/Hyperlipidemia, Heart Diseases, Heart Attack, Stroke, Cerebrovascular Accident, Carotid Artery Diseases, Carotid Atherosclerosis, Transient Ischemic Attack
Interventions
99mTc-tilmanocept SPECT/CT scanning
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Atherosclerosis
Interventions
R-alpha lipoic acid
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
50 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Overweight and Obesity, Insulin Resistance, Diabetes, Gestational, Hypertension in Pregnancy, Pre-Eclampsia
Interventions
DHA Supplements, Placebo Supplements
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Myocardial Inflammation, Rheumatoid Arthritis, Coronary Artery Disease, Myocardial Strain
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Peripheral Arterial Disease
Interventions
Pro-Omega, ProOmega Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
19 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Mineola, New York